drugset / Trial / NCT01153425
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Phase 4
Completed
33 enrolled
University of Pennsylvania
Eli Lilly and Company · collabNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collabNovartis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized into either a teriparatide (Forteo™) or zoledronic acid (Reclast™) group.
Timeline
- Start
- 2008-07
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Teriparatide | Protein / enzyme biologic | 20 ug | Subcutaneous |
| Comparator | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |